Skills and experience: Andreas joined the Board following the acquisition of Alexion, where he had been a director since 2010. Andreas was previously at Novartis where he had been Group Head of Technical Operations and Quality and, from 2006 until 2010, served on the Executive Committee. He was Global CEO of the Generics Division of Sandoz from 2004 to 2008, having originally joined in 1985. Andreas earned his PhD in pharmaceutical sciences from the University of Erlangen-Nuremberg and received his executive training in general management and leadership from IMD in Lausanne; INSEAD in Fontainebleau; and Harvard Business School. Other appointments: Andreas is Chairman and Managing Partner of InterPharmaLink AG and a director of various privately-held biotech and pharmaceutical companies. He is a member of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership.

Source: AstraZeneca PLC on 03/16/2023